Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.
Talipexole is a new dopamine autoagonist with putative preferential activity on presynaptic dopamine receptors. In a double-blind, placebo-controlled study, we tested the drug's safety and efficacy in 13 adult men with Gilles de la Tourette's syndrome. The drug was poorly tolerated because of clinically significant sedation and dizziness. Tics did not improve at tolerable doses. These findings suggest that talipexole has no role in the regular management of tic disorders.
Goetz
C G
CG
Department of Neurological Sciences, Rush University/Rush-Presbyterian St. Luke's Medical Center, Chicago, Illinois 60612.
Stebbins
G T
GT
Thelen
J A
JA
D000328:Adult; D001381:Azepines / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D014743:Videotape Recording
D001381:Azepines; D015259:Dopamine Agents; D011954:Receptors, Dopamine; C024763:talipexole